Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

toothbrush

- PMLiVE

Bayer’s Eylea cleared for wider use in Europe

Macular oedema treatment reached €759m in sales last year

- PMLiVE

Sanofi joins WHO-backed diabetes mHealth programme

Becomessole pharma partner for Be Healthy, Be Mobile's diabetes arm

- PMLiVE

Russian innovation at the crossroads

Despite improvements, investors face rising risks

- PMLiVE

2015: A year of promise and connectivity

How could technology impact healthcare in this year and what will be the key trends to follow?

- PMLiVE

Mapping KOL relationships

Network maps can deliver a wealth of information

Gilead Sciences

Gilead’s Sovaldi wins NICE approval but faces access delay

The Institute also recommends Janssen's hepatitis C drug Olysio

- PMLiVE

Future gazing: What does 2015 hold for NICE?

Undermined by the CDF, the Institute is set to face a number of challenges this year

Sanofi reception

Sanofi gets green light for Lantus follow-up Toujeo

Once-daily basal insulin gains FDA approval for diabetes

- PMLiVE

Eisai adds online patient stories to Belviq marketing

Belviq Voices 'online community' will featureweight loss patient experiences

- PMLiVE

Actavis gets FDA nod for new antibiotic

Avycaz is the fifth antibiotic to gain US approval in recent months

Bristol-Myers Squibb (BMS) building

BMS buys immunotherapy specialist Flexus in $1.2bn deal

And signs new cancer research partnership with Rigel

Shire Basingstoke

Shire boosts orphan drug pipeline with Meritage Pharma deal

Firm will also acquire global rights to Meritage’s phase III OBS compound

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links